CELU Key Statistics, Chart & Performance
The current stock price of CELU is 1.21 USD. In the past month the price decreased by -40.1%. In the past year, price decreased by -47.39%.
CELU Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About CELU
Company Profile
Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. The company is headquartered in Florham Park, New Jersey and currently employs 123 full-time employees. The company went IPO on 2019-05-23. The firm is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. The company develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Company Info
CELULARITY INC-A
170 Park Ave
Florham Park NEW JERSEY US
Employees: 120
Phone: 19087682170
CELULARITY INC-A / CELU FAQ
What does CELULARITY INC-A do?
Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. The company is headquartered in Florham Park, New Jersey and currently employs 123 full-time employees. The company went IPO on 2019-05-23. The firm is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. The company develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
What is the stock price of CELULARITY INC-A today?
The current stock price of CELU is 1.21 USD. The price increased by 9.01% in the last trading session.
Does CELULARITY INC-A pay dividends?
CELU does not pay a dividend.
What is the ChartMill technical and fundamental rating of CELU stock?
CELU has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the market expecting CELU stock to perform?
7 analysts have analysed CELU and the average price target is 6.12 USD. This implies a price increase of 405.79% is expected in the next year compared to the current price of 1.21.
Should I buy CELU stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CELU.
What is the next earnings date for CELU stock?
CELULARITY INC-A (CELU) will report earnings on 2026-05-07, after the market close.
CELU Technical Analysis
CELU Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CELU. CELU may be in some trouble as it scores bad on both profitability and health.
CELU Financial Highlights
Over the last trailing twelve months CELU reported a non-GAAP Earnings per Share(EPS) of -3.34. The EPS decreased by -119.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.65% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CELU Forecast & Estimates
7 analysts have analysed CELU and the average price target is 6.12 USD. This implies a price increase of 405.79% is expected in the next year compared to the current price of 1.21.
For the next year, analysts expect an EPS growth of -752.63% and a revenue growth 27.37% for CELU